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Abstract: The prognosis for glioblastoma patients is, at best, poor, with the median time of 
survival after diagnosis measured in months. As such, there is much need for the rapid 
development of potent and novel treatments. Herein, we report our preliminary findings on 
the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with 
low micromolar activity against a particularly resistant glioblastoma cell culture, providing a 
new platform for future development of a new therapy in this area. 
Glioblastoma are the most common form of malignant brain tumours in adults and account 
for 12-15% of all primary intracranial neoplasms. They are aggressive, often resistant to 
treatment and primarily affect adults aged between 45 and 75 years old. The median survival 
time is 6 months with only 28% of glioblastoma patients surviving more than one year, and 
only 3% of patients surviving more than three years.
1 
Undoubtedly, the prognosis is poor, and 
whilst the standard best treatment procedure is currently maximal safe surgical resection 
followed by simultaneous radiotherapy to the resection site and chemotherapy with 
temozolomide, in what is referred to as the “Stupp protocol”, this regimen merely leads to a 
mean survival of 14.6 months and a two year survival of 26.5%.
2
 As such, glioblastoma are 
largely considered to be currently incurable. Such stark statistics highlight a much needed 
investment in the research surrounding treatment, not only to improve survival times per se, 
but survival with an excellent quality of life. 
Several years ago, we proposed that indoles (1 and 2) may be considered to be hybrid 
structures between the naturally occurring anticancer compound indole-3-carbinol (I3C, 3) 
  
and the known privileged structure 2-phenylindole (4, Figure 1), and have shown that the 
“hybrid” structure 1 possesses modest anticancer activity against glioblastoma cell lines and 
short term cultures, whilst 2, although more active against these cultures, has been too 
unstable to enable further study.
3
 However, recent studies into the mechanism of action of 1 
have suggested that the precise biological mechanisms of action of the two hybrid structures 
(1 and 2) may in fact be different,
4 
suggesting that, at least from a mechanistic point of view, 
these indoles are not hybrid structures, but should be treated as different compound classes, 
both of which happen to possess activity against glioma cell cultures. Herein, this study 
outlines the preliminary work carried out into I3C (3) and its derivatives (5) and highlights 
some important findings which have led to new lead compounds for future development into 
glioblastoma chemotherapies. 
Figure 1 The structures of 1-4 and the Markush structure (5) showing the preliminary SAR investigated. For R, 
R1 and X – see Figure 3. 
Indole-3-carbinol (I3C, 3) is found naturally in particularly high concentrations in cruciferous 
vegetables such as cabbage, kale, cauliflower and sprouts and is by far the most studied 
component of such vegetables, a class of plant that appears to contain many anticancer 
agents.
5
 In vitro and in vivo, I3C forms many degradation products (Figure 2),
6
 and their 
formation and properties have been an active area of study for over 30 years.
7,8
 During this 
time, I3C has been shown to be active against a wide variety of cancers, including breast,
9
 
colon,
10
 prostate,
11,12
 and most recently by us, against glioblastoma.
3
 Many of I3C’s 
metabolites have also been shown to have wide ranging effects in biological assays.
11-13
 
Furthermore, Fang and co-workers have elegantly shown that small molecule derivatives of 
  
I3C possess antitumour activity through the modulation of functions in multiple cancer-
related pathways and are highly active in a subset of cancer cell lines from the National 
Cancer Institute (NCI-60) panel. However, it has been commented by those authors that the 
mechanism underlying the selective activity of their best I3C derivative remains 
uncharacterised.
14,15
 
 
Figure 2 The known metabolites/degradation products of indole-3-carbinol: 3,3’-diindolylmethane (DIM, 6), a 
cyclic tetramer (CTet), the first linear trimer (LTr1), indolo[3,2-b]carbazole (ICZ), a cyclic trimer (CTr) and a 
linear tetramer (LTet). 
 
The simplest and mostly widely studied I3C metabolite is 3,3’-diindolylmethane (DIM, 6). 
The mechanism for the conversion of I3C to DIM is well known, and proceeds under very 
mild acidic conditions via a 3-methyleneindolinium intermediate (7, Scheme 1).
7
 Based on 
this mechanism, DIM is known to be an active form of the prodrug I3C,
16
 and is formed from 
I3C rapidly under the conditions of the stomach.
17,18
  
 
Scheme 1 The acid-catalysed conversion of I3C into DIM. 
In vitro it is believed that I3C is first converted into a cysteine-adduct, which is taken up by 
the cell and passed into the nucleus, where it is converted into DIM. It has been shown that 
I3C doesn’t appear to exist in significant concentrations inside the cell at all, suggesting that 
  
I3C is not directly responsible for any biological effects, and instead it is a metabolite of I3C 
that is the important active species.
17
  
Previously, compound 2 was shown to be a marked improvement over its parent compound, 
I3C (3), against the U87 glioblastoma cell line, where I3C had an IC50 of 526 μM, whereas 
compound 2 has an IC50 of 176 μM, an effect that was ascribed to the presence of the 2-
phenyl group in 2.
3
 
Based on these observations, and in conjunction with our own recent findings, it is now 
evident that compounds 1 and 2 cannot be part of the same pharmacological class when 
compared in their entirety. Comparing the structure of a prodrug (2) to the structure of 1 is 
not evaluating like for like, and it is more appropriate to compare the structure of 1 with the 
active species DIM (or DIM analogue), which obviously share fewer structural features, and 
would therefore be unlikely to be considered as two members of the same chemical class. 
 
Preliminary SAR of fragments 
The 3-carbinol group  
The 3-carbinol group of I3C is considered an important feature for biological activity due to 
its role in the degradation to the active species, DIM. Its mechanism involving the loss of 
water and concomitant stabilisation of the carbocation through conjugation can be seen in 
Scheme 1. Consequently, by extending the carbon chain from hydroxymethane to 
hydroxyethane, thus no longer having the hydroxyl group conjugated with an electronegative 
atom on which the positive charge can rest, should prevent the formation of the active dimer, 
and biological activity would be reduced. Likewise, by the same argument, indole and 
2-phenylindole should also be less active since they have no 3-substituent and thus a 3,3’-
diindolylmethane metabolic product cannot be formed. 
  
 
Figure 3 SAR studied, grouped by feature being investigated. 
In relation to two established glioblastoma cell lines (U87, U251) and three short-term 
glioblastoma cultures (IN1472, IN1528, IN1760) against which the compounds were tested, 
indole itself and 2-phenylindole (4) had EC50 values that were too high to calculate based on 
the concentration ranges used (entries 1 and 4), suggesting a lack of activity in glioblastoma 
for these compounds. However, compound 2 was shown to have EC50 values in the range of 
10 – 1430 μM, demonstrating a large increase in activity upon inclusion of the 3-carbinol 
group (compare entries 2 and 4), results which were supported by the data for indole vs. I3C 
(EC50(I3C) = 119-1580 μM, entries 1 and 3). 
Table 1 Comparison of EC50 values ( M). 
Entry Compound 
U87 
(μM) 
U251 
(μM) 
IN1472 
(μM) 
IN1528 
(μM) 
IN1760 
(μM) 
1 indole
a,b
 - - - - - 
2 2
b
 30 ± 8 130 ± 15 480 ± 7 10 ± 8 1430 ± 394 
3 I3C, 3
b
 290 ± 19 390 ± 5 950 ± 232 119 ± 6 1580 ± 438 
  
4 4
a,b
 - - - - - 
5 DIM, 6
b,c
 - 280 ± 5 - 440 ± 153 230 ± 98 
6 8
b
 580 ± 71 1220 ± 82 
1950 ± 
268 
1740 ± 198 4570 ± 767 
7 9 110 ± 9 250 ± 37 350 ± 27 4 ± 1 330 ± 62 
8 10
c
 - 600 ± 280 - >10000 >10000 
9 11
c
 - 140 ± 13 - 440 ± 60 650 ± 79 
10 12
c
 - 1760 ± 10 - 5820 ± 260 >10000 
11 13
c
 - 1240 ± 172 - 3990 ± 526 1080 ± 139 
12 14
c
 - 50 ± 8 - 270 ± 35 50 ± 17 
a EC50 not reached. 
b Commercially available from Sigma-Aldrich (UK). c U87 and IN1472 not tested. Errors are 
standard deviations of experiments run at least in triplicate. 
 
Extension of the 3-carbinol group (entries 6 and 7) yields less conclusive results. Comparing 
I3C with its hydroxyethane analogue 8 (entries 3 and 6) shows that 8 has consistently worse 
activity across all five cell lines and cultures on which they were tested. However, the 2-
phenyl analogues (2 and 9, entries 2 and 7) show much less consistency, with compound 2 
having better activity against the two established cell lines U87 and U251, whereas its 
hydroxyethyl analogue (9) has better activity against the three short term cultures IN1472, 
IN1528 and IN1760, and is particularly active against IN1528 (EC50 = 4  M). That said, 
when comparing 2 with 3, and 8 with 9, with respect to the 2-phenyl group, it is evident that 
the phenyl ring increases efficacy across all cells lines and cultures studied. 
 
The effect of N-substituents 
Since a cationic intermediate (7, Scheme 1) is involved in the conversion of I3C to its active 
form, DIM, the stability of this intermediate presumably impacts on the amount of DIM 
produced in vitro. Therefore, by increasing the stability of intermediate 7 sufficiently to 
enable dimerisation to occur, the yield of DIM should increase, and the observed anticancer 
  
activity should also increase accordingly. Conversely, destabilising the cation should result in 
lower anticancer activity since the formation of the intermediate (and hence dimer) would be 
retarded. Three analogues were produced in order to probe this hypothesis (Figure 3, 10-12). 
Two N-substituents were chosen which are both electron withdrawing groups but to differing 
extents (the acetyl group being much less electron withdrawing than the tosyl group), 
structural features which should impact upon the rate of formation of cation 7, and thus 
anticancer activity. Acetyl groups are known to be hydrolysable and so could be expected to 
be cleaved in the cell, especially in the presence of numerous cellular proteases. However, the 
rate of hydrolysis compared to the rate of dimerisation would determine in which order these 
two processes would be likely to occur. For example, if the acetyl group is removed too 
easily (Scheme 2, k1Hydrol>>k1Dim), then I3C would be readily formed and the rate of 
dimerisation would likely be the same as the rate of dimerisation of I3C, so no difference in 
activity would be expected when comparing 12 to  I3C. However, if the acetyl group is 
sufficiently stable, it should retard the rate of formation of the dimer (based on the 
mechanism shown in Scheme 1), which should also result in a reduced activity. These 
competing pathways are shown in Scheme 2. 
 
Scheme 2 The two potential pathways to DIM from compound 12. 
 
To ascertain if the inclusion of a hydrolysable group is significant in these compounds, an 
analogue containing a non-hydrolysable N-substituent should be included for comparison.  
  
This non-hydrolysable group should be as chemically similar as possible to the acetyl group 
in order to keep the analogue as otherwise similar. Therefore, the group should have electron 
withdrawing mesomeric properties, be relatively small, and be a hydrogen bond acceptor.  A 
substituent that fulfils all of these criteria is the tosyl group. As such, the N-tosyl and N-acetyl 
analogues of I3C (compounds 11 and 12 respectively, shown in Figure 3) were synthesised 
and tested as direct comparisons to I3C, in addition to the N-acetyl analogue of 2, namely 
compound 10. 
When screened against the glioblastoma cell cultures (U251, IN1528 and IN1760), the effect 
of the N-acetyl group shows a clear negative effect on anticancer activity, with both I3C and 
compound 2 (entries 2 and 3) having better activity than their N-acetyl analogues 10 and 12 
(entries 8 and 10). Based on the established prodrug nature of I3C to convert to its active 
DIM form in biological assays, these results imply that the acetyl group is not effectively 
removed, either by hydrolysis or by enzymatic activity, and the formation of the dimer, 
through a mechanism similar to that shown in Scheme 1, is prevented. That said, it cannot be 
ruled out that the role of the NH group is important for binding, or that, through N-
substitution, the ability of the compounds to directly bind to cellular targets in their “prodrug” 
form has been altered. 
Conversely, an improvement in activity was noted between I3C and its N-tosyl analogue 11 
(entries 3 and 9) against U251 and IN1760. This was somewhat unexpected, since an electron 
withdrawing group on nitrogen should destabilise the intermediate cation, therefore reducing 
the amount of the resultant diindolylmethane formed, as seen with the N-acetyl derivatives. 
However, despite this contradictory behaviour, these findings agree with Chen et al. who 
show that N-sulfonyl analogues of I3C have a significant improvement in activity compared 
to I3C itself when studied against prostate cancer cell lines, and that in addition to chemical 
stability, the N-tosyl group’s unique stereoelectronic properties allowed their lead compound 
to interact more effectively with target proteins compared with indole-3-carbinol; all 
analogous amide derivatives tested were inactive in Chen’s assays.19  
From these results, it seems apparent that N-substitution alone is not simply an electronic 
change, but that the specific substituent itself may have a more complicated effect. Such an 
effect may be related to the ability of the prodrug to form the active dimer, the interaction of 
the N-substituent with a protein, or the solubility and uptake of either the prodrug or active 
compound. The fact that the effect of the two N-substituents on these fragments is so distinct 
  
(entries 8, 9 and 10) suggests that this position would be a viable option to investigate further, 
especially since some selectivity between cell types can be observed.
14,15
 
 
The heteroaromatic core  
An alternative way of affecting the electronic environment at positon-1 of I3C is to change 
the heteroatom completely. The analogous heteroaromatic systems benzofuran and 
benzothiophene lack a hydrogen at position-1, which may be significant, since the potential 
for this hydrogen to be abstracted from the cationic intermediate may lead to a significant 
stabilisation of the 3-methyleneindolinium intermediate (7) during the metabolism of I3C to 
DIM. In addition, benzofuran contains the more electronegative oxygen in place of a 
nitrogen, which would therefore lead to a less readily-formed (less stable) cationic 
intermediate.  Conversely, since sulfur is less electronegative than nitrogen, the formation of 
a cationic intermediate from a benzothiophene analogue would be less difficult. That said, to 
our knowledge, there are no occurrences of an S or O equivalent of the dimerisation outlined 
in Scheme 1. Moreover, potentially important hydrogen-bond donor interactions will be lost 
when replacing NH with either O or S, all features which should impact on biological 
activity. As a result of these potentially complex factors, the choice between testing a 
benzofuran or benzothiophene analogue became fairly arbitrary, and the decision to 
synthesise the benzothiophene analogue 13 for testing was ultimately down to commercial 
availability of the required starting material. 
Comparing the EC50 values of I3C and 13 (entries 3 and 11), reveals there is no clear superior 
compound, with I3C having better activity against the U251 and IN1528 cultures and 
compound 13 having marginally better activity against the IN1760 cell culture, however, 
taken on balance, compound 13 does appear slightly less effective overall than the parent 
compound. 
 
The effect of diindolylmethanes 
The final comparison within this series was to investigate the necessity of using the prodrug 
at all. It is known that the metabolism of I3C to DIM doesn’t occur in quantitative yields in 
  
vitro, so one might assume that by testing the isolated active dimers, activity would increase 
in parallel with the increase in bioavailability of the active species (cLogPI3C = 1.43; 
cLogPDIM = 4.20).
20
 
To investigate this hypothesis and the necessity of using the prodrugs (I3C and 2) at all, 
dimers 6 and 14 were evaluated. 
The EC50 values for 2, I3C (3), DIM (6) and compound 14 (entries 2, 3, 5 and 12) show some 
convincing trends. Despite the significantly reduced solubility of DIM compared to I3C, and 
the complex mechanism of I3C uptake,
17
 the isolated active compound 14 has markedly 
higher anticancer activity than its prodrug 2 against the resistant IN1760 cell culture. 
What is particularly interesting is that compound 14 has higher activity than DIM in all three 
glioblastoma cultures tested. It was initially assumed that the role of the 2-phenyl group in 
compound 2 was to aid in the formation of the diindolylmethane metabolite. However, the 
higher activity of compound 14 compared to DIM indicates that the 2-phenyl group has a 
beneficial effect on the active form of the drug as well. This isn’t entirely unexpected, as a 
number of 2-phenylindoles are known to have activities in a wide variety of therapeutic 
areas.
21
  
What is also noteworthy is the considerable improvement of both diindolylmethanes (but 
especially compound 14) against the chemoresistant IN1760 culture. This is of particular 
interest as it suggests that this class of compounds not only have reasonable activity against 
the established cell line U251, they may also have a broad spectrum of activity against 
otherwise chemoresistant cells. Since IN1760 is considered by groups that work with such 
short term cultures to be a particularly chemoresistant culture,
22 
analogue 14 may turn out to 
be a useful fragment against chemoresistant tumours upon further optimisation. 
 
 
A total of five structural features were investigated as part of this work, and unsurprisingly, 
the key structural feature of the prodrug form was the 3-carbinol group, as has been seen in 
other cancers.
8-11,16,17,19,23,24
 Presumably, without this group the active form of the drug could 
not form. The nitrogen of the indole core also appears to be important, since replacing this 
  
scaffold with a benzothiophene scaffold, as in compound 13, drastically reduced activity 
against certain cell lines. N-substituted analogues of the prodrug appear to be a viable way of 
affecting a significant change in activity, with the N-tosyl substituent (compound 11) 
appearing to improve activity.
19
  
The 2-phenyl group consistently showed an improvement in activity both in the prodrug and 
active form of the drug (2 and 14, entries 2 and 12), a structural feature which should be 
included as standard in any future work. 
Overall, the most promising compound of this series is compound 14. Since it was shown that 
N-substituents have a significant effect on the activity of I3C, N-substituted analogues of 
diindolylmethane 14 will be investigated in due course. 
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